The stratification of disease for personalised medicines

The stratification of disease for personalised medicines
Publication date:  16/04/2009
Publication ref: 
This paper explores how public and private bodies engaged in biomedical research in the UK could work together to realise the significant mutual benefits that will accrue by accelerating the development and adoption of personalised medicine.

It represents the views of members of the ABPI R&D and Medical communities in response to a recent invitation from OSCHR and the TSB to present prioritised recommendations for the way forward. Industry believes that this paper is timely and that it sits very comfortably within the broader strategic perspective of its wider dialogue with Government concerning how the UK can preserve its position as an international location of choice for innovative drug and diagnostic research and clinical development.

Document size: 208KB



Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.